SANJIVANI PARANTERAL LTD.
Latest filings
- Closure of Trading Window for the Second Quarter and Half Year Ended, 30th September, 2026 · Compliance
- Trading Window Closed Ahead of Q2 FY27 Results · Compliance
- Clarification on use of warrant issue proceeds · Fund Raising
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and exports pharmaceutical formulations — injectables, oral solids and nutraceuticals — with 78.50% of FY26 revenue from overseas markets. Injectables are the largest product line at ₹346.15 million (53.45% of revenue), followed by tablets at ₹279.14 million. A new IV infusion plant at Pune (SPL Infusion) began commercial production in December 2025 and contributed ₹2.7 crore in Q4 FY26; management has guided FY27 revenue of ₹60-65 crore from this plant and ₹80-85 crore from the base business. The company also holds a 45% stake in a Prague nutraceutical joint venture. Q4 FY26 was hit by Middle East shipping disruptions tied to US-Iran tensions, leaving about ₹6 crore of exports undispatched. Materials account for 63.4% of revenue, the dominant cost item.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SANJIVANI PARANTERAL LTD.'s filed financials and exchange disclosures
What does SANJIVANI PARANTERAL LTD. do?
SANJIVANI PARANTERAL LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is SANJIVANI PARANTERAL LTD. profitable?
Yes. Over the trailing twelve months SANJIVANI PARANTERAL LTD. reported a net profit of ₹9.69 Cr on revenue of ₹72 Cr.
Does SANJIVANI PARANTERAL LTD. pay a dividend?
Yes. The dividend yield is 0.27% at the current price. It paid out 9% of its profit as dividend in FY26.
Is SANJIVANI PARANTERAL LTD. debt-free?
No. It reported borrowings of ₹14 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹13 Cr after cash. Debt stands at 0.28× equity. That is higher than 68% of its 166 Pharmaceuticals peers.
Is SANJIVANI PARANTERAL LTD. expensive compared with its peers?
On trailing P/E, SANJIVANI PARANTERAL LTD. ranks 52 of 158 in Pharmaceuticals — cheaper than 68% of them, against an industry median of 32.0×. This is a position, not a valuation judgement.
How much does the SANJIVANI PARANTERAL LTD. share price move in a day?
On a typical session SANJIVANI PARANTERAL LTD. moves 1.60% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track SANJIVANI PARANTERAL LTD.'s announcements?
Every NSE and BSE filing by SANJIVANI PARANTERAL LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.